Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2020-02-05 Share Issue/Capital Cha…
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Appendix 3G 12 pages 253.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G Notification of issue, conversion or payment up of equity +securities' and contains detailed information about the issuance of securities under an employee incentive scheme, including the number and type of securities, recipients, and terms. It is a formal notification to the ASX (Australian Securities Exchange) about equity securities issued, which aligns with announcements related to share issues or capital changes. The document is not a full financial report, earnings release, or management discussion, but a regulatory announcement about securities issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed data, not just a brief announcement or a report publication notice.
2020-02-05 English
Appendix 3Ys 11 pages 512.9KB
Regulatory Filings
2020-02-05 English
Appendix 4C - Quarterly 7 pages 323.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 31 January 2020, titled 'Quarterly Cashflow report – Period ending 31 December 2019'. It includes detailed financial data such as consolidated statements of cash flows for the quarter and year to date, cash balances, financing activities, and estimated cash outflows for the next quarter. It also contains an Appendix 4C Quarterly report, which is a regulatory requirement for entities listed on the ASX to report quarterly cash flows and financing activities. The document is approximately 13,776 characters long, indicating it is a substantive report rather than a brief announcement. The content focuses on quarterly financial performance and cash flow details, consistent with an Interim / Quarterly Report. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q2 2020
2020-01-30 English
Appendix 3G 12 pages 252.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the ASX (Australian Securities Exchange) regarding the notification of issue, conversion, or payment up of equity securities. It details the issuance of securities under an employee incentive scheme, including the number and type of securities issued, and references ASX rules and codes. The content is regulatory in nature, focused on notifying the exchange about changes in the company's capital structure, specifically the issuance of new equity securities. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or other filing types. The document is lengthy (15,000 characters) and contains detailed information about the securities issued, confirming it is not merely an announcement of a report but the actual notification of a capital change event.
2020-01-19 English
AGC Agreement termination paves way for commercial partner 2 pages 173.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 20 December 2019 regarding the termination of a manufacturing and joint venture agreement between Regeneus Ltd and AGC Inc. It details the conversion of payments into equity, share issuance, and changes in commercial partnership arrangements. The content focuses on a corporate agreement termination and capital structure changes (equity issuance to AGC). There are no financial statements, quarterly or annual results, or detailed financial performance data. The document is not a report but an announcement of a corporate transaction involving capital changes and shareholder structure. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on company financing activities and capital structure changes.
2019-12-19 English
Proposed issue of Securities - RGS 5 pages 27.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by REGENEUS LTD. It details the number of securities to be issued, the issue price, the proposed issue date, and compliance with ASX listing rules. There is no financial performance data, earnings information, or management discussion. The content focuses on the capital raising activity and issuance of new shares. Therefore, this fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the placement, confirming it is not a brief notice or a report publication announcement.
2019-12-19 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.